Insider Selling: Sotera Health (NASDAQ:SHC) Director Sells $158,727,600.00 in Stock

Sotera Health Company (NASDAQ:SHC) Director Pincus & Co. Warburg sold 9,720,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $16.33, for a total transaction of $158,727,600.00. Following the sale, the director directly owned 34,102,952 shares in the company, valued at approximately $556,901,206.16. This trade represents a 22.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Pincus & Co. Warburg also recently made the following trade(s):

• On Monday, November 10th, Pincus & Co. Warburg sold 18,000,000 shares of Sotera Health stock. The stock was sold at an average price of $15.65, for a total value of $281,700,000.00.

Sotera Health Trading Up 1.1%

Shares of NASDAQ SHC opened at $16.75 on Monday. The company has a current ratio of 2.38, a quick ratio of 2.18 and a debt-to-equity ratio of 4.04. Sotera Health Company has a one year low of $9.53 and a one year high of $17.78. The business has a 50-day moving average price of $16.31 and a two-hundred day moving average price of $14.37. The firm has a market capitalization of $4.76 billion, a PE ratio of 88.16 and a beta of 1.81.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. Sotera Health had a net margin of 4.82% and a return on equity of 43.69%. The business had revenue of $311.31 million during the quarter, compared to analyst estimates of $303.63 million. Sotera Health has set its FY 2025 guidance at 0.810-0.860 EPS. As a group, analysts predict that Sotera Health Company will post 0.61 earnings per share for the current fiscal year.

Institutional Trading of Sotera Health

A number of institutional investors and hedge funds have recently made changes to their positions in SHC. Charles Schwab Investment Management Inc. increased its holdings in shares of Sotera Health by 5.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,415,282 shares of the company’s stock valued at $16,502,000 after acquiring an additional 68,087 shares during the last quarter. Deutsche Bank AG boosted its position in Sotera Health by 1,902.2% during the first quarter. Deutsche Bank AG now owns 165,605 shares of the company’s stock worth $1,931,000 after purchasing an additional 157,334 shares during the period. Invesco Ltd. grew its holdings in Sotera Health by 10.4% during the first quarter. Invesco Ltd. now owns 306,398 shares of the company’s stock valued at $3,573,000 after purchasing an additional 28,892 shares during the last quarter. Nuveen LLC acquired a new position in Sotera Health during the first quarter valued at approximately $4,433,000. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of Sotera Health by 3,690.1% in the first quarter. Caitong International Asset Management Co. Ltd now owns 2,691 shares of the company’s stock valued at $31,000 after purchasing an additional 2,620 shares during the period. Institutional investors and hedge funds own 91.03% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SHC. JPMorgan Chase & Co. boosted their price target on shares of Sotera Health from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Piper Sandler lifted their price objective on Sotera Health from $15.00 to $17.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. BMO Capital Markets initiated coverage on Sotera Health in a research note on Thursday, November 13th. They issued an “outperform” rating and a $19.00 target price on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Sotera Health in a research report on Tuesday, December 2nd. Finally, Barclays raised their price target on Sotera Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.80.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.